# A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

> **NCT06620848** · PHASE2 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 49 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** HRS-4642 monotherapy
- **DRUG:** HRS-4642 and adebrelimab combination therapy

## Key facts

- **NCT ID:** NCT06620848
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06620848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06620848, "A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06620848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*